MG
CRSP icon

Mather Group’s CRISPR Therapeutics CRSP Stock Holding History

Mather Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35
Closed -$1.67K – 1923
2026
Q1 		$1.67K Buy
+35
New +$1.85K ﹤0.01% 1721
2025
Q2 		– Sell
-250
Closed -$8.51K – 850
2025
Q1 		$8.51K Hold
250
– – ﹤0.01% 1294
2024
Q4 		$9.84K Hold
250
– – ﹤0.01% 1252
2024
Q3 		$11.7K Sell
250
-150
-38% -$7.61K ﹤0.01% 1151
2024
Q2 		$27.3K Buy
400
+150
+60% +$8.68K ﹤0.01% 1185
2024
Q1 		$15.7K Buy
+250
New +$17.9K ﹤0.01% 1102

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mather Group's CRSP Position: Q2 2026 in Review

Mather Group sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 35 shares — an estimated $1.67K sold.

Mather Group first reported a position in CRSP in Q1 2024 and held it in 6 quarters. The position peaked at $27.3K in Q2 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Mather Group reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mather Group sold 35 CRISPR Therapeutics shares in Q2 2026, an estimated $1.67K.
  • Mather Group first reported a position in CRISPR Therapeutics in Q1 2024 and held it in 6 quarters.
  • Mather Group's CRISPR Therapeutics position peaked at $27.3K in Q2 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.